Free
Pain Medicine  |   April 2003
Dialysis Delivery of an Adenosine A1Receptor Agonist to the Pontine Reticular Formation Decreases Acetylcholine Release and Increases Anesthesia Recovery Time
Author Affiliations & Notes
  • Diana Tanase, M.D.
    *
  • Helen A. Baghdoyan, Ph.D.
  • Ralph Lydic, Ph.D.
  • *Ph.D. Candidate, Department of Anesthesiology, University of Michigan, and Department of Neuroscience and Anatomy, The Pennsylvania State University College of Medicine. †Professor, Department of Anesthesiology, University of Michigan.
  • Received from the Department of Anesthesiology, University of Michigan, Ann Arbor, Michigan, and the Department of Neuroscience and Anatomy, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania.
Article Information
Pain Medicine
Pain Medicine   |   April 2003
Dialysis Delivery of an Adenosine A1Receptor Agonist to the Pontine Reticular Formation Decreases Acetylcholine Release and Increases Anesthesia Recovery Time
Anesthesiology 4 2003, Vol.98, 912-920. doi:
Anesthesiology 4 2003, Vol.98, 912-920. doi:
THE purine nucleoside adenosine functions as a neuromodulator in the central nervous system. Adenosine is a product of adenosine triphosphate (ATP) hydrolysis, and some cholinergic neurons corelease adenosine and ATP. 1,2 There is good evidence that adenosine is an endogenous sleep-promoting molecule. 3,4 The adenosine antagonist caffeine enhances wakefulness and disrupts normal sleep. 5 Stimulation of adenosine receptors in unanesthetized animals mimics sleep deprivation. 6 Preclinical studies also have shown that adenosine agonists increase sleep 7,8 and adenosine antagonists reduce sleep. 9 In vivo  microdialysis permits unique insights regarding brain adenosine concentrations during differing states of behavioral arousal. In basal forebrain sites known to regulate levels of arousal 10 and in cerebral cortex, 11 adenosine progressively increases during extended wakefulness and decreases during periods of recovery sleep. These findings support the concept that adenosine is sleep-promoting and prompt the question of whether adenosine in brain stem regions modulating sleep influences the generation or maintenance of anesthetic states.
The medial pontine reticular formation (mPRF) is a brain stem region contributing to the regulation of sleep, 12,13 anesthesia, 14–16 and antinociception. 17,18 No previous studies have determined whether adenosine A1receptors in the mPRF modulate acetylcholine release in mPRF and time required for recovery of wakefulness following anesthesia. Therefore, this study examined the hypothesis that microdialysis administration of an adenosine A1receptor agonist into feline mPRF would decrease acetylcholine release and prolong recovery from halothane anesthesia.
Materials and Methods
Animal Model
All procedures involving animals were reviewed and approved by the University of Michigan Committee on Use and Care of Animals (Ann Arbor, Michigan) and strictly adhered to the recommendations in the Guide for the Care and Use of Laboratory Animals  . 19 Four adult male cats were anesthetized with isoflurane and implanted with electrodes to enable objective recording of arousal states. Multiple lines of previous evidence made the cat the logical choice for these preclinical studies. First, most of the cellular-level data regarding brain stem regulation of arousal states have been derived from the cat. 12,20,21 Second, use of the cat made it possible to interpret the current results relative to evidence that pontine acetylcholine release is significantly altered by opioids, 15 halothane, 14 and ketamine. 16 Third, the loss of wakefulness associated with sleep or anesthesia causes respiratory depression. An extensive body of evidence from cats shows that alterations in pontine cholinergic neurotransmission cause upper airway hypotonia, decreased minute ventilation, and diminished responsiveness to hypercapnia (reviewed in Lydic and Baghdoyan 13). Finally, previous neurobiological studies of cats support the working hypothesis that neuronal networks that have evolved to generate naturally occurring states of sleep and wakefulness contain neurons that, when altered by anesthetic molecules, generate the physiologic and behavioral traits comprising anesthetic states. 22,23 Thus, the current use of the cat provided another opportunity to evaluate the hypothesis that sleep neurobiology contributes novel insights into the mechanisms of anesthetic action.
As described in detail elsewhere, 24,25 implanted electrodes permit long-term recording of electroencephalogram, electromyogram, and eye movements (electrooculogram). These electrodes were encased in acrylic and permanently affixed to the calvarium. Cylinders were imbedded in the acrylic for attachment to a Kopf 880 (David Kopf Instruments, Tujunga, CA) head holder. The Kopf 880 cylinders prevent nociceptive stimulation by permitting subsequent stereotaxic positioning without touching tissue. A craniotomy with a removable cover provided brain access for a microdialysis probe. 15 Cats were allowed 3 weeks to recover before beginning experiments.
Acetylcholine Measurement Using Microdialysis and High-performance Liquid Chromatography with Electrochemical Detection
The probes used for microdialysis (CMA/Microdialysis, Stockholm, Sweden) had a 70-mm shaft and a polycarbonate membrane (2 mm length, 0.5 mm diameter, 20 kd pore size). Probes were perfused continuously with Ringer's solution at a flow rate of 3 μl/min using a CMA/100 pump. Before each experiment, a standard curve was created with six concentrations of acetylcholine ranging from 0.1 to 1 pmol. Prior to the in vivo  portion of each experiment, preexperimental probe recoveries were determined by in vitro  dialysis of a known concentration of acetylcholine. These probes typically have an acetylcholine recovery rate of approximately 8%. The true amount of pontine acetylcholine is unknown, and the acetylcholine values are therefore expressed as pmol/10 min of dialysis. Likewise, the precise amount of pontine tissue affected by dialysis delivery of adenosinergic drugs is unknown. One of the advantages of microdialysis over microinjection is that dialysis drug delivery influences a smaller area of tissue than microinjection. 26 Diffusion rates and tissue area affected by drug vary as a function of drug properties and tissue. In the medial pontine reticular formation, microinjection effects have been shown to vary within 1 mm. 27 One may speculate that microdialysis affects a more limited region of tissue surrounding the probe.
Each 30-μl sample was injected into an LC4C amperometric detector (Bioanalytical Systems, West Lafayette, IN). The electroactive product (H2O2) produced by an immobilized enzyme reactor column passed over the electrochemical detector and generated chromatograms proportional to the amount of acetylcholine in the dialysis sample. The area under each chromatographic peak was integrated with a computer using the ChromGraph Report and Control programs (Bioanalytical Systems). The percentages of acetylcholine recovery from the probe were compared by t  test to values obtained after removing the probe from the brain. This comparison of preexperimental and postexperimental probe recoveries ensured that variation in acetylcholine reflected neurochemical changes rather than changes in performance of the dialysis probe.
Drug Preparation
The adenosine receptor agonist N6-p-sulfophenyladenosine (SPA; Sigma-Aldrich Corp., St. Louis, MO) was used because of its high selectivity for A1versus  A2receptors (affinity ratio of A1/A2= 120). 28 SPA was prepared in Ringer's solution in concentrations of 0.088 or 8.8 mm. The adenosine receptor antagonist 8-cyclopentyl-1, 3-dipropylxanthine (DPCPX; Sigma-Aldrich) shows a 700-fold selectivity for the A1receptor versus  the A2receptor. 29 DPCPX was dissolved in dimethyl sulfoxide (Sigma-Aldrich) and then diluted to 100 μm in Ringer's solution, with a final dimethyl sulfoxide concentration of 0.008%. Antagonist + agonist coadministration consisted of 8.8 mm SPA and 100 μm DPCPX prepared in Ringer's solution. Drug solutions were made fresh prior to every experiment. Drug solutions were filtered, pH adjusted to 6.0 ± 0.4, maintained at room temperature, and protected from light. These drug concentrations were chosen as equimolar to the concentration of cholinergic agonist shown by previous studies to alter sleep 30 or acetylcholine release 31 when administered into the pontine reticular formation. A limitation of microdialysis drug delivery is the inability to specify the quantity of administered drug. Since the current dialysis probes exhibit an 8% acetylcholine recovery, one can assume dialysis drug delivery of approximately 8% of the dialyzed concentration. If this assumption is correct, the delivered drug concentrations would have been approximately 7 or 700 μm SPA and 8 μm DPCPX.
Experimental Procedures and Design
Each experiment began by anesthetizing a cat with 3% halothane. The trachea then was intubated with a cuffed pediatric endotracheal tube (size 3.5–4.5 French), and the cat was placed in a Kopf stereotaxic frame and connected to a mechanical ventilator. End-tidal halothane and carbon dioxide fractions were monitored continuously with an Ohmeda Rascal II spectrometer (Datex-Ohmeda, Madison, WI). Ventilation and inspired halothane concentration were adjusted to maintain end-tidal halothane at 1.5% and end-tidal carbon dioxide at 30 mmHg. Oxygen saturation and heart rate were monitored with an Ohmeda Biox 3700 Pulse Oximeter (Datex-Ohmeda). Blood pressure was monitored using a Critikon Dinamap (Critikon, Tampa, FL), and body temperature was measured with a rectal thermometer (Yellow Springs Instrument Co, Yellow Springs, OH) throughout the experiment. A T500 T/Pump Heat Therapy System (Gaymar, Orchard Park, NY) was used to maintain body temperature at 37°C. A microdialysis probe was aimed for the mPRF or cerebellar cortex using a stereotaxic atlas. 32 Stereotaxic coordinates for the mPRF dialysis sites were posterior 1–3, lateral 1–3, and horizontal −5. Microdialysis sites in the cerebellar cortex were posterior 10, lateral 2–3, and horizontal 5.
This study used an intensive within-subjects design. Each experiment was divided into two phases (fig. 1). Care was taken to ensure that evaluation of the effects of adenosinergic compounds was not confounded by significant variations in duration of halothane anesthesia (fig. 1, lines A–D). The first phase involved microdialysis for simultaneous collection of acetylcholine and drug delivery (fig. 1, lines B–C). The second phase involved quantification of postanesthetic recovery time (fig. 1, lines D–E). Prior to the microdialysis portion of the study, the probe was positioned stereotaxically in the mPRF (fig. 1, lines A–B). The probe was perfused with one of four different solutions: Ringer's solution alone, 0.088 mm SPA, 8.8 mm SPA, or SPA (8.8 mm) plus DPCPX (100 μm). During drug delivery, sequential 30-μl mPRF dialysis samples were collected on ice for quantifying acetylcholine release (fig. 1, lines B–C). The duration of sample collection (fig. 1, lines B–C) always was 180 min. After the microdialysis phase of the experiment was complete (fig. 1, line C), the dialysis probe was removed from the brain (fig. 1, lines C–D). Time required for removal of dialysis probe to cessation of halothane (fig. 1lines C–D) averaged approximately 15 min. After the halothane anesthesia was discontinued (fig. 1, line D), recovery time from anesthesia was quantified (fig. 1, lines D–E). The results quantify variations in time for recovery (interval between lines D and E in fig. 1) as a function of dialysis drug delivery (conditions shown between lines B and C in fig. 1).
Fig. 1. Schematic summarizing the experimental design. Vertical line A indicates the onset of anesthesia (Halothane on). Vertical line B indicates initiation of pontine dialysis. The microdialysis probe was perfused with Ringer's solution, Ringer's solution containing two concentrations of the adenosine A1receptor agonist SPA, or Ringer's solution containing a combination of SPA (8.8 mm) plus the adenosine A1receptor antagonist DPCPX. Acetylcholine was collected continuously throughout the microdialysis phase of the experiment (interval B–C). At the end of the microdialysis phase (vertical line C), the dialysis probe was removed from the brain (interval C–D). Vertical line D indicates the cessation of anesthesia (Halothane off) when the periodic assessment of recovery from halothane anesthesia began. The experiment ended when the recovery score 33 indicated complete recovery (vertical line E).
Fig. 1. Schematic summarizing the experimental design. Vertical line A indicates the onset of anesthesia (Halothane on). Vertical line B indicates initiation of pontine dialysis. The microdialysis probe was perfused with Ringer's solution, Ringer's solution containing two concentrations of the adenosine A1receptor agonist SPA, or Ringer's solution containing a combination of SPA (8.8 mm) plus the adenosine A1receptor antagonist DPCPX. Acetylcholine was collected continuously throughout the microdialysis phase of the experiment (interval B–C). At the end of the microdialysis phase (vertical line C), the dialysis probe was removed from the brain (interval C–D). Vertical line D indicates the cessation of anesthesia (Halothane off) when the periodic assessment of recovery from halothane anesthesia began. The experiment ended when the recovery score 33indicated complete recovery (vertical line E).
Fig. 1. Schematic summarizing the experimental design. Vertical line A indicates the onset of anesthesia (Halothane on). Vertical line B indicates initiation of pontine dialysis. The microdialysis probe was perfused with Ringer's solution, Ringer's solution containing two concentrations of the adenosine A1receptor agonist SPA, or Ringer's solution containing a combination of SPA (8.8 mm) plus the adenosine A1receptor antagonist DPCPX. Acetylcholine was collected continuously throughout the microdialysis phase of the experiment (interval B–C). At the end of the microdialysis phase (vertical line C), the dialysis probe was removed from the brain (interval C–D). Vertical line D indicates the cessation of anesthesia (Halothane off) when the periodic assessment of recovery from halothane anesthesia began. The experiment ended when the recovery score 33 indicated complete recovery (vertical line E).
×
Quantification of Postanesthetic Recovery
To evaluate postanesthetic emergence, a recovery score developed for humans 33 was modified for use in the current study. The recovery score was determined at each of the following time points after turning off the halothane: every min for the first 10 min, every 5 min up to 1 h, every 15 min up to 1.5 h, every hour up to 4 h, and at 24 h. This resulted in a total of 26 time points per experiment at which anesthetic recovery was evaluated. The five criteria for recovery score were provided by measures of (1) motor activity, (2) respiration, (3) blood pressure (BP) and heart rate (HR), (4) responsiveness, and (5) oxygen saturation and skin color. These variables were evaluated and scored as follows:
  1. Motor activity: Spontaneous motor activity was scored as 0 if no movement was observed; 1 when the head or one or two limbs moved; and 2 when all four limbs moved and the cat started walking.

  2. Respiration: No spontaneous respiratory activity was scored as 0; apparent dyspnea, superficial breathing, or effort to breathe were scored as 1; and deep, regular breathing was scored as 2.

  3. Blood pressure and heart rate. Systolic arterial BP and/or HR variation greater than 50% of the initial values was scored as 0; a 20–50% variation from initial values was scored as 1; and less than 20% variation from initial values was scored as 2.

  4. Responsiveness: Failure to respond to auditory stimulation (head or eye movement toward the sound) was scored as 0; any behavioral sign of responsiveness to auditory stimulation was scored as 1; and full alertness and responsiveness to visual and auditory stimuli was scored as 2.

  5. Oxygen saturation and skin color: Cyanosis was scored as 0; alterations from the normal color, such as pale, dusky, or blotchy discoloration, were scored as 1; and normal pink skin coloration and/or oxygen saturation values above 90% were scored as 2.

For each experiment, at each time point, the total recovery score was determined by summing the scores for dependent measures 1–5. Thus, the maximal score possible was 10 and indicated complete recovery from anesthesia.
Histologic and Statistical Analysis
On completion of in vivo  experiments, brains from all animals were examined histologically to confirm dialysis probe placement in the mPRF or cerebellar cortex. Cats were deeply anesthetized with sodium pentobarbital (35–40 mg/kg intraperitoneal) and perfused transcardially with isotonic saline followed by 10% formalin. Brains were removed, fixed, serially sectioned (40 μm thick), and stained with cresyl violet for histologic localization of microdialysis probe sites. All tissue sections containing dialysis probe–induced lesions were digitized and compared with a brain stem atlas. 32 
Postanesthetic recovery scores are reported as mean ± SD. Recovery scores from experiments in which the same drug was administered were averaged at each of the 26 time points. Linear regression analysis was used to quantify recovery score as a function of time for Ringer's solution (control), SPA, and SPA + DPCPX dialysis conditions. Analyses were performed using multiple linear comparisons to evaluate significant differences in slopes and intercepts (GraphPad Prism 3.0 Software Inc., San Diego, CA). One-way analysis of variance (ANOVA) and Tukey-Kramer procedures compared recovery scores following Ringer's solution, 0.088 mm SPA, and 8.8 mm SPA at 15 min, 45 min, and 24 h after drug dialysis completion. Acetylcholine release as a function of dialysis drug delivery was evaluated using ANOVA and the Tukey-Kramer procedure. Probability values of P  < 0.05 were regarded as statistically significant.
Results
Pontine Dialysis with SPA Delayed Emergence from Halothane Anesthesia
The pontine region where drugs were delivered by microdialysis is illustrated in figure 2. Histologic analyses confirmed that all pontine dialysis sites were localized to the mPRF, which lies within the gigantocellular tegmental field as described by Berman. 32 
Fig. 2. Histologic localization of a dialysis site. Sagittal section of cat brain stem shows a typical microdialysis site (arrow) localized within the medial pontine reticular formation (mPRF). Inset indicates location of the mPRF on a midsagittal schematic of the cat brain and schematizes a microdialysis probe used to deliver drugs and collect endogenously released acetylcholine. Comparison of histologic sections from all cats to a cat brain stem atlas 32 confirmed mPRF dialysis probe placement for all animals used in this study. 7G = genu of facial nerve; 6 = abducens nucleus; 6N = abducens nerve; IC = inferior colliculus; TB = trapezoid body.
Fig. 2. Histologic localization of a dialysis site. Sagittal section of cat brain stem shows a typical microdialysis site (arrow) localized within the medial pontine reticular formation (mPRF). Inset indicates location of the mPRF on a midsagittal schematic of the cat brain and schematizes a microdialysis probe used to deliver drugs and collect endogenously released acetylcholine. Comparison of histologic sections from all cats to a cat brain stem atlas 32confirmed mPRF dialysis probe placement for all animals used in this study. 7G = genu of facial nerve; 6 = abducens nucleus; 6N = abducens nerve; IC = inferior colliculus; TB = trapezoid body.
Fig. 2. Histologic localization of a dialysis site. Sagittal section of cat brain stem shows a typical microdialysis site (arrow) localized within the medial pontine reticular formation (mPRF). Inset indicates location of the mPRF on a midsagittal schematic of the cat brain and schematizes a microdialysis probe used to deliver drugs and collect endogenously released acetylcholine. Comparison of histologic sections from all cats to a cat brain stem atlas 32 confirmed mPRF dialysis probe placement for all animals used in this study. 7G = genu of facial nerve; 6 = abducens nucleus; 6N = abducens nerve; IC = inferior colliculus; TB = trapezoid body.
×
Figure 3shows that dialysis delivery of 8.8 mm SPA into the mPRF significantly increased time required for recovery from halothane anesthesia compared to recovery time following dialysis with Ringer's solution alone. The three functions shown in figure 3were determined from recovery scores obtained after dialysis with Ringer's solution, 0.088 mm SPA, or 8.8 mm SPA (fig. 1, lines B–C). The function labeled Ringer's had a slope of 0.18 and an intercept of 5.4, representing the control profile of emergence from halothane anesthesia (fig. 3). Following control dialysis with Ringer's solution, all cats completely recovered in 30 min after delivery of halothane ended. Dialysis delivery of 0.088 mm SPA produced a recovery score profile similar to the control, with a slope of 0.14 and an intercept of 4.95 (fig. 3). All cats that received the low concentration of SPA (0.088 mm) recovered within 30–45 min after cessation of halothane. Dialysis delivery of 8.8 mm SPA increased postanesthetic recovery time. The recovery score determined following treatment with 8.8 mm SPA had a slope of 0.05 ± 0.007 and a y-axis intercept of 3.24 ± 0.19, reflecting the delayed emergence from anesthesia (fig. 3). Multiple regression comparisons indicated a significant difference (F = 22.7;df  = 2, 83;P  < 0.0001) between the recovery score slopes for SPA (8.8 mm) and Ringer's solution (control). The histograms of figure 4show that dialysis delivery of 8.8 mm SPA significantly delayed recovery for up to 4 h following discontinuation of halothane. The figure 4recovery scores were obtained during the interval indicated in figure 1between lines D and E.
Fig. 3. Time course of recovery from anesthesia following pontine microdialysis. For recovery score (ordinate), 10 = full recovery and 0 = no recovery. Each data point represents the mean ± SD of at least three individual recovery scores from different experiments in different animals. Regression analyses for each of these treatment conditions generated linear functions.
Fig. 3. Time course of recovery from anesthesia following pontine microdialysis. For recovery score (ordinate), 10 = full recovery and 0 = no recovery. Each data point represents the mean ± SD of at least three individual recovery scores from different experiments in different animals. Regression analyses for each of these treatment conditions generated linear functions.
Fig. 3. Time course of recovery from anesthesia following pontine microdialysis. For recovery score (ordinate), 10 = full recovery and 0 = no recovery. Each data point represents the mean ± SD of at least three individual recovery scores from different experiments in different animals. Regression analyses for each of these treatment conditions generated linear functions.
×
Fig. 4. Pontine administration of SPA slowed recovery from anesthesia. Data are presented as recovery score for Ringer's solution (control; n = 3 experiments in three cats), 0.088 mm SPA (n = 4 experiments in four cats), and 8.8 mm SPA (n = 4 experiments in four cats). Bars represent mean + SD recovery scores. Recovery scores are shown at 15 min after cessation of halothane (A  ), 45 min after cessation of halothane (B  ), 4 h after cessation of halothane (C  ), and 24 h after cessation of halothane. *P  < 0.01 compared with Ringer's solution (control).
Fig. 4. Pontine administration of SPA slowed recovery from anesthesia. Data are presented as recovery score for Ringer's solution (control; n = 3 experiments in three cats), 0.088 mm SPA (n = 4 experiments in four cats), and 8.8 mm SPA (n = 4 experiments in four cats). Bars represent mean + SD recovery scores. Recovery scores are shown at 15 min after cessation of halothane (A 
	), 45 min after cessation of halothane (B 
	), 4 h after cessation of halothane (C 
	), and 24 h after cessation of halothane. *P 
	< 0.01 compared with Ringer's solution (control).
Fig. 4. Pontine administration of SPA slowed recovery from anesthesia. Data are presented as recovery score for Ringer's solution (control; n = 3 experiments in three cats), 0.088 mm SPA (n = 4 experiments in four cats), and 8.8 mm SPA (n = 4 experiments in four cats). Bars represent mean + SD recovery scores. Recovery scores are shown at 15 min after cessation of halothane (A  ), 45 min after cessation of halothane (B  ), 4 h after cessation of halothane (C  ), and 24 h after cessation of halothane. *P  < 0.01 compared with Ringer's solution (control).
×
Coadministration of DPCPX Partially Blocked the SPA-induced Increase in Halothane Recovery Time
The SPA-induced delay in recovery from halothane anesthesia was significantly reduced by coadministration of the adenosine A1receptor antagonist DPCPX. Figure 5summarizes the functions generated by linear regression analysis of recovery scores obtained after dialysis with Ringer's solution, DPCPX + SPA, and SPA alone. By min 60, the mean recovery score following administration of DPCPX + SPA was 9.67, indicating complete postanesthetic recovery. The linear function representing postanesthetic recovery scores following DPCPX + SPA had a slope of 0.09 ± 0.01 and an intercept of 4.89 ± 0.27. These values were intermediate between slope and intercept values for Ringer's solution and 8.8 mm SPA. Multiple linear regression analysis demonstrated that DPCPX and SPA coadministration caused a significantly shorter (F = 21;df  = 2, 78;P  < 0.0001) wake-up time than 8.8 mm SPA dialysis alone.
Fig. 5. Time course of recovery from anesthesia following dialysis delivery of Ringer's solution (control), the adenosine A1receptor agonist (SPA), or the antagonist plus agonist (DPCPX + SPA). These studies in three animals all used the 8.8-mm SPA concentration. Recovery score is expressed as a function of time with 10 = full recovery and 0 = no recovery. Each data point represents the mean ± SD of at least three individual recovery scores from different experiments. Linear functions for Ringer's solution and SPA are the same as those shown in figure 3. DPCPX + SPA significantly suppressed the slope attenuation induced by 8.8 mm SPA.
Fig. 5. Time course of recovery from anesthesia following dialysis delivery of Ringer's solution (control), the adenosine A1receptor agonist (SPA), or the antagonist plus agonist (DPCPX + SPA). These studies in three animals all used the 8.8-mm SPA concentration. Recovery score is expressed as a function of time with 10 = full recovery and 0 = no recovery. Each data point represents the mean ± SD of at least three individual recovery scores from different experiments. Linear functions for Ringer's solution and SPA are the same as those shown in figure 3. DPCPX + SPA significantly suppressed the slope attenuation induced by 8.8 mm SPA.
Fig. 5. Time course of recovery from anesthesia following dialysis delivery of Ringer's solution (control), the adenosine A1receptor agonist (SPA), or the antagonist plus agonist (DPCPX + SPA). These studies in three animals all used the 8.8-mm SPA concentration. Recovery score is expressed as a function of time with 10 = full recovery and 0 = no recovery. Each data point represents the mean ± SD of at least three individual recovery scores from different experiments. Linear functions for Ringer's solution and SPA are the same as those shown in figure 3. DPCPX + SPA significantly suppressed the slope attenuation induced by 8.8 mm SPA.
×
Dialysis Administration of 8.8 mm SPA into the Cerebellar Cortex Did Not Delay Recovery from Anesthesia
Figure 6compares recovery scores obtained following cerebellar SPA administration with recovery scores obtained following mPRF Ringer's solution (control) and mPRF SPA administration. Following dialysis delivery of SPA into cerebellum, two cats achieved complete recovery by min 30, and the third cat recovered completely by min 45. Multiple linear regression analyses demonstrate that cerebellar administration of SPA failed to delay recovery from anesthesia, and that the recovery score was significantly different from the delayed recovery caused by 8.8 mm SPA delivered to mPRF (F = 20.53;df  = 2, 75;P  < 0.0001). Thus, the delay in recovery was significantly dependent on SPA administration into the medial pontine reticular formation. There was no significant difference in the duration of halothane administration between experiments that dialyzed the mPRF with Ringer's solution (control), experiments that dialyzed the mPRF with SPA or SPA + DPCPX, and experiments that dialyzed the cerebellar cortex with SPA.
Fig. 6. Time course of recovery from anesthesia comparing dialysis administration of SPA into the medial pontine reticular formation (mPRF) and cerebellar cortex (cerebellum). Linear regression analysis compared recovery scores from anesthesia after dialysis delivery of 8.8 mm SPA to the cerebellar cortex to recovery scores following mPRF dialysis of 8.8 mm SPA and Ringer's solution (control). Recovery score is expressed on a scale of 0–10 with 10 = full recovery and 0 = no recovery. Each data point represents the mean ± SD of at least three individual recovery scores from different experiments. Linear functions for Ringer's solution and SPA are the same as those shown in figure 3. The linear function for recovery scores following cerebellar administration of SPA revealed a slope of 0.113 and a y-intercept of 5.88.
Fig. 6. Time course of recovery from anesthesia comparing dialysis administration of SPA into the medial pontine reticular formation (mPRF) and cerebellar cortex (cerebellum). Linear regression analysis compared recovery scores from anesthesia after dialysis delivery of 8.8 mm SPA to the cerebellar cortex to recovery scores following mPRF dialysis of 8.8 mm SPA and Ringer's solution (control). Recovery score is expressed on a scale of 0–10 with 10 = full recovery and 0 = no recovery. Each data point represents the mean ± SD of at least three individual recovery scores from different experiments. Linear functions for Ringer's solution and SPA are the same as those shown in figure 3. The linear function for recovery scores following cerebellar administration of SPA revealed a slope of 0.113 and a y-intercept of 5.88.
Fig. 6. Time course of recovery from anesthesia comparing dialysis administration of SPA into the medial pontine reticular formation (mPRF) and cerebellar cortex (cerebellum). Linear regression analysis compared recovery scores from anesthesia after dialysis delivery of 8.8 mm SPA to the cerebellar cortex to recovery scores following mPRF dialysis of 8.8 mm SPA and Ringer's solution (control). Recovery score is expressed on a scale of 0–10 with 10 = full recovery and 0 = no recovery. Each data point represents the mean ± SD of at least three individual recovery scores from different experiments. Linear functions for Ringer's solution and SPA are the same as those shown in figure 3. The linear function for recovery scores following cerebellar administration of SPA revealed a slope of 0.113 and a y-intercept of 5.88.
×
Dialysis Delivery of SPA Decreased Acetylcholine Release, and This Effect Was Blocked by DPCPX
Figure 7Aplots acetylcholine release measured during a typical experiment in which dialysis delivery of 8.8 mm SPA decreased mPRF acetylcholine. Figure 7Bsummarizes mPRF acetylcholine release during dialysis with Ringer's solution (control) and during dialysis delivery of 0.088 or 8.8 mm SPA. ANOVA revealed a significant SPA-induced decrease in acetylcholine release (F = 22.4;df  = 2, 117;P  < 0.0001). Dialysis with 8.8 mm SPA (fig. 7B, solid bar) decreased acetylcholine release to 78.6% of control (fig. 7B, hatched bar). Multiple comparison statistic showed that the lower concentration of SPA (0.088 mm) did not significantly alter acetylcholine release (fig. 7B, shaded bar). Figure 8shows that coadministration of DPCPX with SPA blocked the SPA-induced decrease in mPRF acetylcholine release (F = 39.9;df  = 2, 102;P  < 0.0001).
Fig. 7. Dialysis administration of SPA decreased acetylcholine release. (A  ) Time course of a typical experiment. (Inset  ) Sagittal view of cat brain with a dialysis probe delivering sulfophenyladenosine (SPA, 8.8 mm) into the medial pontine reticular formation (mPRF) and dialysis samples containing acetylcholine (ACh) collected every 10 min. Bars represent amount of acetylcholine detected in each 30-μl sample. Mean ± SD acetylcholine during dialysis with Ringer's solution (control) was 0.22 ± 0.02 pmol/10 min of dialysis. Mean ± SD acetylcholine during dialysis with SPA was 0.17 ± 0.04 pmol/10 min. (B  ) Comparison of acetylcholine release during mPRF dialysis with Ringer's solution (n = 40 dialysis samples) and during dialysis with 0.088 mm SPA (n = 40) and 8.8 mm SPA (n = 40). Data were obtained from four experiments in four cats. Analysis of variance followed by Tukey-Kramer post hoc  analysis demonstrate a statistically significant decrease in acetylcholine release below Ringer's solution levels following dialysis of 8.8 mm SPA (*P  < 0.01).
Fig. 7. Dialysis administration of SPA decreased acetylcholine release. (A 
	) Time course of a typical experiment. (Inset 
	) Sagittal view of cat brain with a dialysis probe delivering sulfophenyladenosine (SPA, 8.8 mm) into the medial pontine reticular formation (mPRF) and dialysis samples containing acetylcholine (ACh) collected every 10 min. Bars represent amount of acetylcholine detected in each 30-μl sample. Mean ± SD acetylcholine during dialysis with Ringer's solution (control) was 0.22 ± 0.02 pmol/10 min of dialysis. Mean ± SD acetylcholine during dialysis with SPA was 0.17 ± 0.04 pmol/10 min. (B 
	) Comparison of acetylcholine release during mPRF dialysis with Ringer's solution (n = 40 dialysis samples) and during dialysis with 0.088 mm SPA (n = 40) and 8.8 mm SPA (n = 40). Data were obtained from four experiments in four cats. Analysis of variance followed by Tukey-Kramer post hoc 
	analysis demonstrate a statistically significant decrease in acetylcholine release below Ringer's solution levels following dialysis of 8.8 mm SPA (*P 
	< 0.01).
Fig. 7. Dialysis administration of SPA decreased acetylcholine release. (A  ) Time course of a typical experiment. (Inset  ) Sagittal view of cat brain with a dialysis probe delivering sulfophenyladenosine (SPA, 8.8 mm) into the medial pontine reticular formation (mPRF) and dialysis samples containing acetylcholine (ACh) collected every 10 min. Bars represent amount of acetylcholine detected in each 30-μl sample. Mean ± SD acetylcholine during dialysis with Ringer's solution (control) was 0.22 ± 0.02 pmol/10 min of dialysis. Mean ± SD acetylcholine during dialysis with SPA was 0.17 ± 0.04 pmol/10 min. (B  ) Comparison of acetylcholine release during mPRF dialysis with Ringer's solution (n = 40 dialysis samples) and during dialysis with 0.088 mm SPA (n = 40) and 8.8 mm SPA (n = 40). Data were obtained from four experiments in four cats. Analysis of variance followed by Tukey-Kramer post hoc  analysis demonstrate a statistically significant decrease in acetylcholine release below Ringer's solution levels following dialysis of 8.8 mm SPA (*P  < 0.01).
×
Fig. 8. Comparison of acetylcholine release during dialysis delivery of an adenosine A1receptor agonist (SPA, n = 40 dialysis samples) and the combined dialysis delivery of the adenosine A1receptor antagonist (DPCPX) and agonist (SPA, n = 30). Experiments were performed at least three times in four different cats. Analysis of variance followed by Tukey-Kramer post hoc  analysis demonstrate that coadministration of DPCPX with SPA blocked the statistically significant decrease in acetylcholine release induced by dialysis of 8.8 mm SPA (*P  < 0.01).
Fig. 8. Comparison of acetylcholine release during dialysis delivery of an adenosine A1receptor agonist (SPA, n = 40 dialysis samples) and the combined dialysis delivery of the adenosine A1receptor antagonist (DPCPX) and agonist (SPA, n = 30). Experiments were performed at least three times in four different cats. Analysis of variance followed by Tukey-Kramer post hoc 
	analysis demonstrate that coadministration of DPCPX with SPA blocked the statistically significant decrease in acetylcholine release induced by dialysis of 8.8 mm SPA (*P 
	< 0.01).
Fig. 8. Comparison of acetylcholine release during dialysis delivery of an adenosine A1receptor agonist (SPA, n = 40 dialysis samples) and the combined dialysis delivery of the adenosine A1receptor antagonist (DPCPX) and agonist (SPA, n = 30). Experiments were performed at least three times in four different cats. Analysis of variance followed by Tukey-Kramer post hoc  analysis demonstrate that coadministration of DPCPX with SPA blocked the statistically significant decrease in acetylcholine release induced by dialysis of 8.8 mm SPA (*P  < 0.01).
×
Discussion
Adenosine is relevant to anesthesiology in part because of compelling evidence that adenosine alters hyperalgesia and neuropathic pain. 34–38 Adenosine infusion reduces the requirement for isoflurane, 39 and the current results show that time required for recovery from halothane anesthesia was significantly increased by pontine delivery of an adenosine A1receptor agonist. Normal brain acetylcholine concentrations are required for electroencephalographic and behavioral arousal. 40 Thus, the finding that pontine acetylcholine was decreased by the adenosine A1receptor agonist is considered below as one potential mechanism modulating the delayed recovery from halothane anesthesia.
Adenosine A1Receptor Agonist Increased Time Required for Recovery from Halothane Anesthesia
N  -methylated xanthine molecules such as caffeine, theobromine, and theophylline all promote arousal. Caffeine ingestion by humans increases latency to sleep onset and reduces the electroencephalographic δ power of non-REM sleep. 41 The ability of caffeine to promote wakefulness is mediated in part by A1adenosine receptors. 5 The data reported here show a significant delay in posthalothane recovery caused by dialysis delivery of the adenosine A1receptor agonist SPA into the medial pontine reticular formation (figs. 3 and 4). The results provide additional support for the view that medial regions of the pontine reticular formation, known to modulate sleep, 12 also contribute to the loss of wakefulness caused by a chemically diverse set of anesthetic agents. As noted previously, acetylcholine release in the pontine reticular formation is significantly decreased by morphine, 42 halothane, 14 fentanyl, 15 and ketamine. 16 
The results are consistent with the interpretation that the SPA-induced increase in postanesthetic recovery time can be modulated by adenosine A1receptors. The delay in postanesthetic recovery caused by dialysis delivery of the adenosine A1receptor agonist varied significantly as a function of agonist concentration (figs. 3 and 4) and was blocked by coadministration of the adenosine A1receptor antagonist DPCPX (fig. 5). Dialysis delivery of the agonist into the cerebellar cortex failed to prolong emergence (fig. 6). Thus, the delayed recovery from halothane anesthesia was site-specific to the mPRF, varied significantly with SPA concentration, and was blocked by an adenosine agonist.
Adenosine A1Receptors Modulate Arousal via  Cholinergic Neurotransmission
Studies of sensory afferent neurons, central nervous system neurons, and efferent motor systems show that adenosine A1receptors alter cholinergic neurotransmission. In sensory neurons, purinergic neuromodulators such as ATP and acetylcholine can activate similar nonselective cation channels via  common intracellular pathways. 43 Adenosine A1receptors inhibit synaptic transmission by decreasing N-type Ca2+current. 44 Adenosine A1receptors exert an inhibitory action on Ca2+entry coupled to acetylcholine release in retina cells. 45 In motor systems, ATP suppresses acetylcholine release via  protein kinase C–coupled purinergic receptors, and adenosine alters quantal acetylcholine release. 46 In central nervous system neurons, acetylcholine release is inhibited by adenosine A1receptors in optic tectum, 47 striatum, 48 cortex, 49,50 and hippocampus. 51 
By what cellular mechanisms might adenosine alter acetylcholine release and arousal? Adenosine inhibits electroencephalographic and behavioral arousal, which are modulated by forebrain and brain stem cholinergic neurons. Basal forebrain cholinergic neurons provide acetylcholine to the cortex, and cortically activated states of wakefulness and REM sleep are associated with greater concentrations of cortical acetylcholine than are states of NREM sleep. 52 Measures of basal forebrain acetylcholine also show that acetylcholine release is greater during wakefulness and REM sleep than during NREM sleep. 53 These microdialysis data are consistent with studies showing that administering adenosine to the basal forebrain decreases wakefulness. 7,54 In contrast, wakefulness is increased by administering an adenosine A1receptor antagonist to the basal forebrain. 55 The foregoing neurochemical studies are supported by electrophysiological evidence. Putatively cholinergic neurons of the magnocellular basal forebrain exhibit the greatest discharge frequency during wakefulness and REM sleep. 56 The discharge of these wake-active basal forebrain neurons is inhibited by an adenosine A1receptor agonist. 57 
Cholinergic neurons in the pontine brain stem also modulate electroencephalographic and behavioral arousal. 13,58 These cholinergic neurons are located in the laterodorsal tegmental and pedunculopontine tegmental nuclei (LDT/PPT) and provide acetylcholine to the mPRF. Neurons in the mPRF do not produce acetylcholine and, in the current study, the acetylcholine measured in the mPRF is known to originate from LDT/PPT neurons. 59 In vitro  electrophysiological recordings found that adenosine A1receptors cause postsynaptic inhibition in approximately two thirds of LDT/PPT neurons. 60 LDT/PPT neuronal excitability also is presynaptically disfacilitated by adenosine A1receptors on presynaptic glutamatergic terminals that innervate the LDT/PPT. 61 Microdialysis delivery of adenosine to the LDT/PPT decreases wakefulness. 7 The foregoing evidence fits well with the current finding that dialysis delivery to the mPRF of the adenosine A1agonist SPA decreased acetylcholine release in the mPRF (figs. 7 and 8). These results also are consistent with the sleep-enhancing effects of microinjecting an adenosine agonist into the pontine reticular formation. 8 
The current results provide a novel extension of the sleep-promoting effects of adenosine by showing that an adenosine A1agonist delays resumption of wakefulness following halothane anesthesia. This extension is consistent with a potentially larger relevance of the current findings for efforts to elucidate the specific neurons and molecules causing traits that characterize the state of anesthesia. The current data support the working hypothesis that adenosine A1receptors in medial regions of the pontine reticular formation, known to modulate sleep states, also contribute to the generation of anesthetic states. 22,23 
Limitations and Conclusions
Four adenosine receptors (A1, A2a, A2b, A3) have been cloned, 44 and use in this study of the agonist SPA restricts conclusions to inferences regarding the A1subtype. Adenosine A1receptors inhibit the release of “virtually every classic neurotransmitter (including glutamate, γ-aminobutyric acid, acetylcholine, norepinephrine, 5-hydroxytryptamine, dopamine, and other transmitters as well)”. 44 Dialysis delivery of SPA was limited to concentrations that were ineffective (0.088 mm) or effective (8.8 mm) in decreasing acetylcholine release. A complete concentration–response curve is required to determine potency and maximal efficacy of SPA. Limitations associated with applying Aldrete and Kroulik's 33 clinical assessment tool to the evaluation of feline posthalothane emergence also are acknowledged. The current data, however, demonstrate the face validity of modifying the human recovery score 33 for operationally quantifying posthalothane recovery in felines (fig. 4). The results encourage future studies aiming to determine if quantitative electroencephalographic analyses can provide a more objective assessment of SPA-induced alterations in levels of arousal. 62 
The current data cannot specify the cellular mechanisms by which the adenosine agonist SPA prolonged the recovery from halothane anesthesia for 4 h (figs. 3–6). Available data, however, permit speculation regarding the long duration of SPA effects on anesthetic recovery time and acetylcholine release. The adenosine A1receptor is coupled to an inhibitory guanine nucleotide–binding (Gi) protein which inhibits adenylyl cyclase and activates calcium and potassium channels. 63 One function of G proteins is signal amplification in the time domain, which may account for the long-duration SPA actions. SPA causes a concentration-dependent activation of G proteins in the medial pontine reticular formation. 64 Although acetylcholine is a neurotransmitter that alters cell excitability with a time course of milliseconds, the cholinergic regulation of sleep and wakefulness has a time course of minutes and hours. 25,30 The modulation of arousal by muscarinic cholinergic receptors in the mPRF involves a signal transduction cascade comprised of adenylate cyclase, a pertussis toxin–sensitive G protein, cyclic AMP, and protein kinase A. 65–67 This cholinergic transduction pathway would be anticipated to cause slow and long-lasting changes in neuronal excitability. 12 The clinical relevance of these cholinergic pathways is illustrated by the ability of acetylcholinesterase inhibitors to reverse propofol-induced unconsciousness. 68 Thus, the current results suggest the working hypothesis that SPA caused a long-lasting depression in acetylcholine and anesthetic recovery time by interacting with cholinergically activated G proteins. This hypothesis is testable and consistent with data showing that in the pons, SPA and the μ-opioid agonist DAMGO cause a partially additive activation of G proteins. 64 
The authors thank Grant Bowman (Research Assistant, Department of Anesthesiology, University of Michigan, Ann Arbor, Michigan), Daniela Hangan, M.D. (Research Assistant, Department of Anesthesiology, University of Michigan), and Carrie A. Lapham, B.A. (Research Secretary IV, Department of Anesthesiology, University of Michigan), for assistance.
References
Richardson PJ, Brown SJ, Bailyes EM, Luzio JP: Ectoenzymes control adenosine modulation of immunoisolated cholinergic synapses. Nature 1987; 327: 232–4Richardson, PJ Brown, SJ Bailyes, EM Luzio, JP
Ralevic V, Burnstock G: Receptors for purines and pyrimidines. Pharmacol Rev 1998; 50: 413–92Ralevic, V Burnstock, G
Haulica I, Ababei L, Branisteanu D, Topoliceanu F: Preliminary data on the possible hypnogenic role of adenosine (letter). J Neurochem 1973; 21: 1019–20Haulica, I Ababei, L Branisteanu, D Topoliceanu, F
Radulovacki M: Role of adenosine in sleep in rats. Rev Clin Bas Pharmacol 1985; 5: 327–39Radulovacki, M
Fredholm BB, Battig K, Holmen J, Nehlig A, Zvartau EE: Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol Rev 1999; 51: 83–133Fredholm, BB Battig, K Holmen, J Nehlig, A Zvartau, EE
Benington JH, Kodali SK, Heller HC: Stimulation of A1adenosine receptors mimics the electroencephalographic effects of sleep deprivation. Brain Res 1995; 692: 79–85Benington, JH Kodali, SK Heller, HC
Portas CM, Thakkar M, Rainnie DG, Greene RW, McCarley RW: Role of adenosine in behavioral state modulation: A microdialysis study in the freely moving cat. Neuroscience 1997; 79: 225–35Portas, CM Thakkar, M Rainnie, DG Greene, RW McCarley, RW
Marks GA, Birabil CG: Enhancement of rapid eye movement sleep in the rat by cholinergic and adenosinergic agonists infused into the pontine reticular formation. Neuroscience 1998; 86: 29–37Marks, GA Birabil, CG
Lin AS, Uhde TW, Slate SO, McCann UD: Effects of intravenous caffeine administered to healthy males during sleep. Depress Anxiety 1997; 5: 21–8Lin, AS Uhde, TW Slate, SO McCann, UD
Porkka-Heiskanen T, Strecker RE, Thakkar M, Bjorkum AA, Greene RW, McCarley RW: Adenosine: A mediator of the sleep-inducing effects of prolonged wakefulness. Science 1997; 276: 1265–8Porkka-Heiskanen, T Strecker, RE Thakkar, M Bjorkum, AA Greene, RW McCarley, RW
Porkka-Heiskanen T, Strecker RE, McCarley RW: Brain site-specificity of extracellular adenosine concentration changes during sleep deprivation and spontaneous sleep: An in vivo microdialysis study. Neuroscience 2000; 99: 507–17Porkka-Heiskanen, T Strecker, RE McCarley, RW
Handbook of Behavioral State Control: Cellular and Molecular Mechanisms. Edited by Lydic R, Baghdoyan HA. Boca Raton, CRC Press, 1999, pp 1–700
Lydic R, Baghdoyan HA: Neurochemical evidence for the cholinergic modulation of sleep and breathing, Sleep Related Breathing Disorders: Experimental Models and Therapeutic Potential. Edited by Carley D, Radulovacki M. New York, Marcel Dekker, 2003, pp 57–91
Keifer JC, Baghdoyan HA, Lydic R: Pontine cholinergic mechanisms modulate the cortical electroencephalographic spindles of halothane anesthesia. A nesthesiology 1996; 84: 945–54Keifer, JC Baghdoyan, HA Lydic, R
Mortazavi S, Thomson J, Baghdoyan HA, Lydic R: Fentanyl and morphine, but not remifentanil, inhibit acetylcholine release in pontine regions modulating arousal. A nesthesiology 1999; 90: 1070–7Mortazavi, S Thomson, J Baghdoyan, HA Lydic, R
Lydic R, Baghdoyan HA: Ketamine and MK-801 decrease ACh release in the pontine reticular formation, slow breathing, and disrupt sleep. Sleep 2002; 25: 617–22Lydic, R Baghdoyan, HA
Kshatri AM, Baghdoyan HA, Lydic R: Cholinomimetics, but not morphine, increase antinociceptive behavior from pontine reticular regions regulating rapid eye movement sleep. Sleep 1998; 21: 677–85Kshatri, AM Baghdoyan, HA Lydic, R
Tanase D, Baghdoyan HA, Lydic R: Microinjection of an adenosine A1agonist into feline medial pontine reticular formation increases tail flick latency to thermal stimulation. A nesthesiology 2002; 97: 1597–601Tanase, D Baghdoyan, HA Lydic, R
Guide for the Care and Use of Laboratory Animals. Washington, DC, National Academy of Sciences Press, 1996
Pace-Schott EF, Hobson JA: The neurobiology of sleep: Genetics, cellular physiology and subcortical networks. Nat Rev Neurosci 2002; 3: 591–605Pace-Schott, EF Hobson, JA
Steriade M, McCarley RW: Brainstem Control of Wakefulness and Sleep. New York, Plenum, 1990
Lydic R: Reticular modulation of breathing during sleep and anesthesia. Curr Opin Pulm Med 1996; 2: 474–81Lydic, R
Lydic R, Baghdoyan HA: Cholinergic contributions to the control of consciousness, Anesthesia: Biologic Foundations. Edited by Yaksh T, Lynch C, Zapol WM, Maze M, Biebuyck JF, Saidman LJ. New York, Lippincott–Raven, 1998, pp 433–50
Ursin R, Sterman MB: A Manual for Standardized Scoring of Sleep and Waking States in the Adult Cat. Los Angeles, Brain Information Services/Brain Research Institute, University of California, 1981
Vazquez J, Lydic R, Baghdoyan HA: The nitric oxide synthase inhibitor NG-nitro-L-arginine increases basal forebrain acetylcholine release during sleep and wakefulness. J Neurosci 2002; 22: 5597–605Vazquez, J Lydic, R Baghdoyan, HA
Microdialysis in the Neurosciences. Edited by Robinson TE, Justice JB. New York, Elsevier, 1991 pp 1–450
Baghdoyan HA, Rodrigo-Angulo ML, McCarley RW, Hobson JA: Site-specific enhancement and suppression of desynchronized sleep signs following cholinergic stimulation of three brain stem regions. Brain Res 1984; 306: 39–52Baghdoyan, HA Rodrigo-Angulo, ML McCarley, RW Hobson, JA
Jacobson KA, Nikodijevic O, Ji X, Berkich DA, Eveleth D, Dean RL, Hiramatsu K-I, Kassell NF, van Galen PJM, Lee KS, Bartus RT: Synthesis and biological activity of N  6-(p  -sulfophenyl)alkyl and N  6-Sulfoalkyl derivatives of adenosine: Water-soluble and peripherally selective adenosine agonists. J Med Chem 1992; 35: 4143–9Jacobson, KA Nikodijevic, O Ji, X Berkich, DA Eveleth, D Dean, RL Hiramatsu, K-I Kassell, NF van Galen, PJM Lee, KS Bartus, RT
Bruns RF, Fergus JH, Badger EW, Bristol JA, Santay LA, Hartman JD, Hays SJ, Huang CC: Binding of the A1-selective adenosine antagonist 8-cyclopentyl-1,3-dipropylxanthine to rat brain membranes. Naunyn Schmiedebergs Arch Pharmacol 1987; 335: 59–63Bruns, RF Fergus, JH Badger, EW Bristol, JA Santay, LA Hartman, JD Hays, SJ Huang, CC
Baghdoyan HA, Lydic R: M2 muscarinic receptor subtype in the feline medial pontine reticular formation modulates the amount of rapid eye movement sleep. Sleep 1999; 22: 835–47Baghdoyan, HA Lydic, R
Baghdoyan HA, Fleegal MA, Lydic R: M2 muscarinic autoreceptors regulate acetylcholine release in the pontine reticular formation. J Pharmacol Exp Ther 1998; 286: 1446–52Baghdoyan, HA Fleegal, MA Lydic, R
Berman AL: The Brain Stem of the Cat. Madison, University of Wisconsin Press, 1968
Aldrete JA, Kroulik D: A postanesthetic recovery score. Anesth Analg 1970; 49: 924–34Aldrete, JA Kroulik, D
Segerdahl M, Irestedt L, Sollevi A: Antinociceptive effect of perioperative adenosine infusion in abdominal hysterectomy. Acta Anaesthesiol Scand 1997; 41: 473–9Segerdahl, M Irestedt, L Sollevi, A
Sjolund KF, Belfrage M, Karlsten R, Segerdahl M, Arner S, Gordh TJR, Sollevi A: Systemic adenosine infusion reduces the area of tactile allodynia in neuropathic pain following peripheral nerve injury: A multi-centre, placebo-controlled study. Eur J Pain 2001; 5: 199–207Sjolund, KF Belfrage, M Karlsten, R Segerdahl, M Arner, S Gordh, TJR Sollevi, A
Gyllenhammar E, Nordfors LO: Systemic adenosine infusions alleviated neuropathic pain. Pain 2001; 94: 121–2Gyllenhammar, E Nordfors, LO
Eisenach JC, Hood D, Curry R: Preliminary efficacy assessment of intrathecal injection of an American formulation of adenosine in humans. A nesthesiology 2002; 96: 29–34Eisenach, JC Hood, D Curry, R
Bantel C, Tobin JR, Li X, Childers SR, Chen SR, Eisenach JC: Intrathecal adenosine following spinal nerve ligation in rat: Short residence time in cerebrospinal fluid and no change in A1receptor binding. A nesthesiology 2002; 96: 103–8Bantel, C Tobin, JR Li, X Childers, SR Chen, SR Eisenach, JC
Segerdahl M, Ekblom A, Sandelin K, Wickman M, Sollevi A: Peroperative adenosine infusion reduces the requirements for isoflurane and postoperative analgesics. Anesth Analg 1995; 80: 1145–9Segerdahl, M Ekblom, A Sandelin, K Wickman, M Sollevi, A
Steriade M: Brain electrical activity and sensory processing during waking and sleep states, Principles and Practice of Sleep Medicine, 3rd edition. Edited by Kryger M, Roth T, Dement W. Philadelphia, WB Saunders, 2000, pp 93–111
Landolt HP, Dijk DJ, Gaus SE, Borbely AA: Caffeine reduces low-frequency delta activity in the human sleep EEG. Neuropsychopharmacology 1995; 12: 79–85Landolt, HP Dijk, DJ Gaus, SE Borbely, AA
Lydic R, Keifer J, Baghdoyan H, Becker L: Microdialysis of the pontine reticular formation reveals inhibition of acetylcholine release by morphine. A nesthesiology 1993; 79: 1003–12Lydic, R Keifer, J Baghdoyan, H Becker, L
Ito K, Dulon D: Nonselective cation conductance activated by muscarinic and purinergic receptors in rat spiral ganglion neurons. Am J Physiol 2002; 282: C1121–35Ito, K Dulon, D
Dunwiddie TV, Masino SA: The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci 2001; 24: 31–55Dunwiddie, TV Masino, SA
Santos PF, Caramelo OL, Carvalho AP, Duarte CB: Adenosine A1receptors inhibit Ca2+channels coupled to the release of ACh, but not of GABA, in cultured retina cells. Brain Res 2000; 852: 10–5Santos, PF Caramelo, OL Carvalho, AP Duarte, CB
Galkin AV, Giniatullin RA, Mukhtarov MR, Svandova I, Grishin SN, Vyskocil F: ATP but not adenosine inhibits nonquantal acetylcholine release at the mouse neuromuscular junction. Eur J Neurosci 2001; 13: 2047–53Galkin, AV Giniatullin, RA Mukhtarov, MR Svandova, I Grishin, SN Vyskocil, F
Poli A, Di Iorio P, Beraudi A, Notari S, Zaccanti F, Villani L, Traversa U: The calcium-dependent [3H]acetylcholine release from synaptosomes of brown trout (Salmo trutta) optic tectum is inhibited by adenosine A1receptors: Effects of enucleation on A1receptor density and cholinergic markers. Brain Res 2001; 892: 78–85Poli, A Di Iorio, P Beraudi, A Notari, S Zaccanti, F Villani, L Traversa, U
Song W-J, Tkatch T, Surmeier DJ: Adenosine receptor expression and modulation of Ca2+channels in rat striatal cholinergic interneurons. J Neurophysiol 2000; 83: 322–32Song, W-J Tkatch, T Surmeier, DJ
Broad RM, Fredholm BB: A1, but not A2A, adenosine receptors modulate electrically stimulated (14C) acetylcholine release from rat cortex. J Pharmacol Exp Ther 1996; 277: 193–7Broad, RM Fredholm, BB
Materi LM, Rasmusson DD, Semba K: Inhibition of synaptically evoked cortical acetylcholine release by adenosine: An in vivo microdialysis study in the rat. Neuroscience 2000; 97: 219–26Materi, LM Rasmusson, DD Semba, K
Sperlagh B, Zsilla G, Vizi E: KATPchannel blockers selectively interact with A1-adenosine receptor mediated modulation of acetylcholine release in the rat hippocampus. Brain Res 2001; 889: 63–70Sperlagh, B Zsilla, G Vizi, E
Jasper HH, Tessier J: Acetylcholine liberation from cerebral cortex during paradoxical (REM) sleep. Science 1971; 172: 601–2Jasper, HH Tessier, J
Vazquez J, Baghdoyan H: Basal forebrain acetylcholine release during REM sleep is significantly greater than during waking. Am J Physiol 2001; 280: R598–601Vazquez, J Baghdoyan, H
Basheer R, Porkka-Heiskanen T, Stenberg D, McCarley RW: Adenosine and behavioral state control: adenosine increases c-Fos protein and AP1 binding in basal forebrain of rats. Brain Res Mol Brain Res 1999; 73: 1–10Basheer, R Porkka-Heiskanen, T Stenberg, D McCarley, RW
Strecker RE, Morairty S, Thakkar M, Porkka-Heiskanen T, Basheer R, Dauphin LJ, Rainnie DG, Portas CM, Greene RW, McCarley RW: Adenosinergic modulation of basal forebrain and preoptic/anterior hypothalamic neuronal activity in the control of behavioral state. Behav Brain Res 2000; 115: 183–204Strecker, RE Morairty, S Thakkar, M Porkka-Heiskanen, T Basheer, R Dauphin, LJ Rainnie, DG Portas, CM Greene, RW McCarley, RW
Szymusiak R, Alam MN, McGinty D: Discharge patterns of neurons in cholinergic regions of the basal forebrain during waking and sleep. Behav Brain Res 2000; 115: 171–82Szymusiak, R Alam, MN McGinty, D
Alam MN, Szymusiak R, Gong H, King J, McGinty D: Adenosinergic modulation of rat basal forebrain neurons during sleep and waking: neuronal recording with microdialysis. J Physiol (Lond) 1999; 521: 679–90Alam, MN Szymusiak, R Gong, H King, J McGinty, D
Baghdoyan HA, Lydic R: Neurotransmitters and neuromodulators regulating sleep, Sleep and Epilepsy: The Clinical Spectrum. Edited by Bazil C, Malow B, Sammaritano M. New York, Elsevier Science, 2002, pp 17–44
Lydic R, Baghdoyan HA: Pedunculopontine stimulation alters respiration and increases ACh release in the pontine reticular formation. Am J Physiol 1993; 264: R544–54Lydic, R Baghdoyan, HA
Rainnie DG, Grunze HC, McCarley RW, Greene RW: Adenosine inhibition of mesopontine cholinergic neurons: Implications for EEG arousal. Science 1994; 263: 689–92Rainnie, DG Grunze, HC McCarley, RW Greene, RW
Arrigoni E, Rainnie DG, McCarley RW, Greene RW: Adenosine-mediated presynaptic modulation of glutamatergic transmission in the laterodorsal tegmentum. J Neurosci 2001; 21: 1076–85Arrigoni, E Rainnie, DG McCarley, RW Greene, RW
Douglas CL, Baghdoyan HA, Lydic R: Prefrontal cortex acetylcholine release, EEG slow-waves, and spindles are modulated by M2 autoreceptors in C57BL/6J mouse. J Neurophysiol 2002; 87: 2817–22Douglas, CL Baghdoyan, HA Lydic, R
Reppert SM, Weaver DR, Stehle JH, Rivkees SA: Molecular cloning and characterization of a rat A1 adenosine receptor that is widely expressed in brain and spinal cord. Mol Endocrinol 1991; 5: 1037–48Reppert, SM Weaver, DR Stehle, JH Rivkees, SA
Tanase D, Martin WA, Baghdoyan HA, Lydic R: G protein activation in rat ponto-mesencephalic nuclei is enhanced by combined treatment with a mu opioid and an adenosine A1receptor agonist. Sleep 2001; 24: 52–62Tanase, D Martin, WA Baghdoyan, HA Lydic, R
Shuman SL, Capece ML, Baghdoyan HA, Lydic R: Pertussis toxin-sensitive G proteins mediate carbachol-induced REM sleep and respiratory depression. Am J Physiol 1995; 269: R308–17Shuman, SL Capece, ML Baghdoyan, HA Lydic, R
Capece ML, Lydic R: cAMP and protein kinase A modulate cholinergic rapid eye movement sleep generation. Am J Physiol 1997; 273: R1430–40Capece, ML Lydic, R
Capece ML, Baghdoyan HA, Lydic R: Carbachol stimulates [35S]guanylyl 5′-(γ-thio)triphosphate binding in rapid eye movement sleep-related brain stem nuclei of rat. J Neurosci 1998; 18: 3779–85Capece, ML Baghdoyan, HA Lydic, R
Meuret P, Backman SB, Bonhomme V, Plourde G, Fiset P: Physostigmine reverses propofol-induced unconsciousness and attenuation of the auditory steady state response and bispectral index in human volunteers. A nesthesiology 2000; 93: 708–17Meuret, P Backman, SB Bonhomme, V Plourde, G Fiset, P
Fig. 1. Schematic summarizing the experimental design. Vertical line A indicates the onset of anesthesia (Halothane on). Vertical line B indicates initiation of pontine dialysis. The microdialysis probe was perfused with Ringer's solution, Ringer's solution containing two concentrations of the adenosine A1receptor agonist SPA, or Ringer's solution containing a combination of SPA (8.8 mm) plus the adenosine A1receptor antagonist DPCPX. Acetylcholine was collected continuously throughout the microdialysis phase of the experiment (interval B–C). At the end of the microdialysis phase (vertical line C), the dialysis probe was removed from the brain (interval C–D). Vertical line D indicates the cessation of anesthesia (Halothane off) when the periodic assessment of recovery from halothane anesthesia began. The experiment ended when the recovery score 33 indicated complete recovery (vertical line E).
Fig. 1. Schematic summarizing the experimental design. Vertical line A indicates the onset of anesthesia (Halothane on). Vertical line B indicates initiation of pontine dialysis. The microdialysis probe was perfused with Ringer's solution, Ringer's solution containing two concentrations of the adenosine A1receptor agonist SPA, or Ringer's solution containing a combination of SPA (8.8 mm) plus the adenosine A1receptor antagonist DPCPX. Acetylcholine was collected continuously throughout the microdialysis phase of the experiment (interval B–C). At the end of the microdialysis phase (vertical line C), the dialysis probe was removed from the brain (interval C–D). Vertical line D indicates the cessation of anesthesia (Halothane off) when the periodic assessment of recovery from halothane anesthesia began. The experiment ended when the recovery score 33indicated complete recovery (vertical line E).
Fig. 1. Schematic summarizing the experimental design. Vertical line A indicates the onset of anesthesia (Halothane on). Vertical line B indicates initiation of pontine dialysis. The microdialysis probe was perfused with Ringer's solution, Ringer's solution containing two concentrations of the adenosine A1receptor agonist SPA, or Ringer's solution containing a combination of SPA (8.8 mm) plus the adenosine A1receptor antagonist DPCPX. Acetylcholine was collected continuously throughout the microdialysis phase of the experiment (interval B–C). At the end of the microdialysis phase (vertical line C), the dialysis probe was removed from the brain (interval C–D). Vertical line D indicates the cessation of anesthesia (Halothane off) when the periodic assessment of recovery from halothane anesthesia began. The experiment ended when the recovery score 33 indicated complete recovery (vertical line E).
×
Fig. 2. Histologic localization of a dialysis site. Sagittal section of cat brain stem shows a typical microdialysis site (arrow) localized within the medial pontine reticular formation (mPRF). Inset indicates location of the mPRF on a midsagittal schematic of the cat brain and schematizes a microdialysis probe used to deliver drugs and collect endogenously released acetylcholine. Comparison of histologic sections from all cats to a cat brain stem atlas 32 confirmed mPRF dialysis probe placement for all animals used in this study. 7G = genu of facial nerve; 6 = abducens nucleus; 6N = abducens nerve; IC = inferior colliculus; TB = trapezoid body.
Fig. 2. Histologic localization of a dialysis site. Sagittal section of cat brain stem shows a typical microdialysis site (arrow) localized within the medial pontine reticular formation (mPRF). Inset indicates location of the mPRF on a midsagittal schematic of the cat brain and schematizes a microdialysis probe used to deliver drugs and collect endogenously released acetylcholine. Comparison of histologic sections from all cats to a cat brain stem atlas 32confirmed mPRF dialysis probe placement for all animals used in this study. 7G = genu of facial nerve; 6 = abducens nucleus; 6N = abducens nerve; IC = inferior colliculus; TB = trapezoid body.
Fig. 2. Histologic localization of a dialysis site. Sagittal section of cat brain stem shows a typical microdialysis site (arrow) localized within the medial pontine reticular formation (mPRF). Inset indicates location of the mPRF on a midsagittal schematic of the cat brain and schematizes a microdialysis probe used to deliver drugs and collect endogenously released acetylcholine. Comparison of histologic sections from all cats to a cat brain stem atlas 32 confirmed mPRF dialysis probe placement for all animals used in this study. 7G = genu of facial nerve; 6 = abducens nucleus; 6N = abducens nerve; IC = inferior colliculus; TB = trapezoid body.
×
Fig. 3. Time course of recovery from anesthesia following pontine microdialysis. For recovery score (ordinate), 10 = full recovery and 0 = no recovery. Each data point represents the mean ± SD of at least three individual recovery scores from different experiments in different animals. Regression analyses for each of these treatment conditions generated linear functions.
Fig. 3. Time course of recovery from anesthesia following pontine microdialysis. For recovery score (ordinate), 10 = full recovery and 0 = no recovery. Each data point represents the mean ± SD of at least three individual recovery scores from different experiments in different animals. Regression analyses for each of these treatment conditions generated linear functions.
Fig. 3. Time course of recovery from anesthesia following pontine microdialysis. For recovery score (ordinate), 10 = full recovery and 0 = no recovery. Each data point represents the mean ± SD of at least three individual recovery scores from different experiments in different animals. Regression analyses for each of these treatment conditions generated linear functions.
×
Fig. 4. Pontine administration of SPA slowed recovery from anesthesia. Data are presented as recovery score for Ringer's solution (control; n = 3 experiments in three cats), 0.088 mm SPA (n = 4 experiments in four cats), and 8.8 mm SPA (n = 4 experiments in four cats). Bars represent mean + SD recovery scores. Recovery scores are shown at 15 min after cessation of halothane (A  ), 45 min after cessation of halothane (B  ), 4 h after cessation of halothane (C  ), and 24 h after cessation of halothane. *P  < 0.01 compared with Ringer's solution (control).
Fig. 4. Pontine administration of SPA slowed recovery from anesthesia. Data are presented as recovery score for Ringer's solution (control; n = 3 experiments in three cats), 0.088 mm SPA (n = 4 experiments in four cats), and 8.8 mm SPA (n = 4 experiments in four cats). Bars represent mean + SD recovery scores. Recovery scores are shown at 15 min after cessation of halothane (A 
	), 45 min after cessation of halothane (B 
	), 4 h after cessation of halothane (C 
	), and 24 h after cessation of halothane. *P 
	< 0.01 compared with Ringer's solution (control).
Fig. 4. Pontine administration of SPA slowed recovery from anesthesia. Data are presented as recovery score for Ringer's solution (control; n = 3 experiments in three cats), 0.088 mm SPA (n = 4 experiments in four cats), and 8.8 mm SPA (n = 4 experiments in four cats). Bars represent mean + SD recovery scores. Recovery scores are shown at 15 min after cessation of halothane (A  ), 45 min after cessation of halothane (B  ), 4 h after cessation of halothane (C  ), and 24 h after cessation of halothane. *P  < 0.01 compared with Ringer's solution (control).
×
Fig. 5. Time course of recovery from anesthesia following dialysis delivery of Ringer's solution (control), the adenosine A1receptor agonist (SPA), or the antagonist plus agonist (DPCPX + SPA). These studies in three animals all used the 8.8-mm SPA concentration. Recovery score is expressed as a function of time with 10 = full recovery and 0 = no recovery. Each data point represents the mean ± SD of at least three individual recovery scores from different experiments. Linear functions for Ringer's solution and SPA are the same as those shown in figure 3. DPCPX + SPA significantly suppressed the slope attenuation induced by 8.8 mm SPA.
Fig. 5. Time course of recovery from anesthesia following dialysis delivery of Ringer's solution (control), the adenosine A1receptor agonist (SPA), or the antagonist plus agonist (DPCPX + SPA). These studies in three animals all used the 8.8-mm SPA concentration. Recovery score is expressed as a function of time with 10 = full recovery and 0 = no recovery. Each data point represents the mean ± SD of at least three individual recovery scores from different experiments. Linear functions for Ringer's solution and SPA are the same as those shown in figure 3. DPCPX + SPA significantly suppressed the slope attenuation induced by 8.8 mm SPA.
Fig. 5. Time course of recovery from anesthesia following dialysis delivery of Ringer's solution (control), the adenosine A1receptor agonist (SPA), or the antagonist plus agonist (DPCPX + SPA). These studies in three animals all used the 8.8-mm SPA concentration. Recovery score is expressed as a function of time with 10 = full recovery and 0 = no recovery. Each data point represents the mean ± SD of at least three individual recovery scores from different experiments. Linear functions for Ringer's solution and SPA are the same as those shown in figure 3. DPCPX + SPA significantly suppressed the slope attenuation induced by 8.8 mm SPA.
×
Fig. 6. Time course of recovery from anesthesia comparing dialysis administration of SPA into the medial pontine reticular formation (mPRF) and cerebellar cortex (cerebellum). Linear regression analysis compared recovery scores from anesthesia after dialysis delivery of 8.8 mm SPA to the cerebellar cortex to recovery scores following mPRF dialysis of 8.8 mm SPA and Ringer's solution (control). Recovery score is expressed on a scale of 0–10 with 10 = full recovery and 0 = no recovery. Each data point represents the mean ± SD of at least three individual recovery scores from different experiments. Linear functions for Ringer's solution and SPA are the same as those shown in figure 3. The linear function for recovery scores following cerebellar administration of SPA revealed a slope of 0.113 and a y-intercept of 5.88.
Fig. 6. Time course of recovery from anesthesia comparing dialysis administration of SPA into the medial pontine reticular formation (mPRF) and cerebellar cortex (cerebellum). Linear regression analysis compared recovery scores from anesthesia after dialysis delivery of 8.8 mm SPA to the cerebellar cortex to recovery scores following mPRF dialysis of 8.8 mm SPA and Ringer's solution (control). Recovery score is expressed on a scale of 0–10 with 10 = full recovery and 0 = no recovery. Each data point represents the mean ± SD of at least three individual recovery scores from different experiments. Linear functions for Ringer's solution and SPA are the same as those shown in figure 3. The linear function for recovery scores following cerebellar administration of SPA revealed a slope of 0.113 and a y-intercept of 5.88.
Fig. 6. Time course of recovery from anesthesia comparing dialysis administration of SPA into the medial pontine reticular formation (mPRF) and cerebellar cortex (cerebellum). Linear regression analysis compared recovery scores from anesthesia after dialysis delivery of 8.8 mm SPA to the cerebellar cortex to recovery scores following mPRF dialysis of 8.8 mm SPA and Ringer's solution (control). Recovery score is expressed on a scale of 0–10 with 10 = full recovery and 0 = no recovery. Each data point represents the mean ± SD of at least three individual recovery scores from different experiments. Linear functions for Ringer's solution and SPA are the same as those shown in figure 3. The linear function for recovery scores following cerebellar administration of SPA revealed a slope of 0.113 and a y-intercept of 5.88.
×
Fig. 7. Dialysis administration of SPA decreased acetylcholine release. (A  ) Time course of a typical experiment. (Inset  ) Sagittal view of cat brain with a dialysis probe delivering sulfophenyladenosine (SPA, 8.8 mm) into the medial pontine reticular formation (mPRF) and dialysis samples containing acetylcholine (ACh) collected every 10 min. Bars represent amount of acetylcholine detected in each 30-μl sample. Mean ± SD acetylcholine during dialysis with Ringer's solution (control) was 0.22 ± 0.02 pmol/10 min of dialysis. Mean ± SD acetylcholine during dialysis with SPA was 0.17 ± 0.04 pmol/10 min. (B  ) Comparison of acetylcholine release during mPRF dialysis with Ringer's solution (n = 40 dialysis samples) and during dialysis with 0.088 mm SPA (n = 40) and 8.8 mm SPA (n = 40). Data were obtained from four experiments in four cats. Analysis of variance followed by Tukey-Kramer post hoc  analysis demonstrate a statistically significant decrease in acetylcholine release below Ringer's solution levels following dialysis of 8.8 mm SPA (*P  < 0.01).
Fig. 7. Dialysis administration of SPA decreased acetylcholine release. (A 
	) Time course of a typical experiment. (Inset 
	) Sagittal view of cat brain with a dialysis probe delivering sulfophenyladenosine (SPA, 8.8 mm) into the medial pontine reticular formation (mPRF) and dialysis samples containing acetylcholine (ACh) collected every 10 min. Bars represent amount of acetylcholine detected in each 30-μl sample. Mean ± SD acetylcholine during dialysis with Ringer's solution (control) was 0.22 ± 0.02 pmol/10 min of dialysis. Mean ± SD acetylcholine during dialysis with SPA was 0.17 ± 0.04 pmol/10 min. (B 
	) Comparison of acetylcholine release during mPRF dialysis with Ringer's solution (n = 40 dialysis samples) and during dialysis with 0.088 mm SPA (n = 40) and 8.8 mm SPA (n = 40). Data were obtained from four experiments in four cats. Analysis of variance followed by Tukey-Kramer post hoc 
	analysis demonstrate a statistically significant decrease in acetylcholine release below Ringer's solution levels following dialysis of 8.8 mm SPA (*P 
	< 0.01).
Fig. 7. Dialysis administration of SPA decreased acetylcholine release. (A  ) Time course of a typical experiment. (Inset  ) Sagittal view of cat brain with a dialysis probe delivering sulfophenyladenosine (SPA, 8.8 mm) into the medial pontine reticular formation (mPRF) and dialysis samples containing acetylcholine (ACh) collected every 10 min. Bars represent amount of acetylcholine detected in each 30-μl sample. Mean ± SD acetylcholine during dialysis with Ringer's solution (control) was 0.22 ± 0.02 pmol/10 min of dialysis. Mean ± SD acetylcholine during dialysis with SPA was 0.17 ± 0.04 pmol/10 min. (B  ) Comparison of acetylcholine release during mPRF dialysis with Ringer's solution (n = 40 dialysis samples) and during dialysis with 0.088 mm SPA (n = 40) and 8.8 mm SPA (n = 40). Data were obtained from four experiments in four cats. Analysis of variance followed by Tukey-Kramer post hoc  analysis demonstrate a statistically significant decrease in acetylcholine release below Ringer's solution levels following dialysis of 8.8 mm SPA (*P  < 0.01).
×
Fig. 8. Comparison of acetylcholine release during dialysis delivery of an adenosine A1receptor agonist (SPA, n = 40 dialysis samples) and the combined dialysis delivery of the adenosine A1receptor antagonist (DPCPX) and agonist (SPA, n = 30). Experiments were performed at least three times in four different cats. Analysis of variance followed by Tukey-Kramer post hoc  analysis demonstrate that coadministration of DPCPX with SPA blocked the statistically significant decrease in acetylcholine release induced by dialysis of 8.8 mm SPA (*P  < 0.01).
Fig. 8. Comparison of acetylcholine release during dialysis delivery of an adenosine A1receptor agonist (SPA, n = 40 dialysis samples) and the combined dialysis delivery of the adenosine A1receptor antagonist (DPCPX) and agonist (SPA, n = 30). Experiments were performed at least three times in four different cats. Analysis of variance followed by Tukey-Kramer post hoc 
	analysis demonstrate that coadministration of DPCPX with SPA blocked the statistically significant decrease in acetylcholine release induced by dialysis of 8.8 mm SPA (*P 
	< 0.01).
Fig. 8. Comparison of acetylcholine release during dialysis delivery of an adenosine A1receptor agonist (SPA, n = 40 dialysis samples) and the combined dialysis delivery of the adenosine A1receptor antagonist (DPCPX) and agonist (SPA, n = 30). Experiments were performed at least three times in four different cats. Analysis of variance followed by Tukey-Kramer post hoc  analysis demonstrate that coadministration of DPCPX with SPA blocked the statistically significant decrease in acetylcholine release induced by dialysis of 8.8 mm SPA (*P  < 0.01).
×